
|Articles|June 1, 2003
PSA doubling of <3 months points to eventual death
Chicago-A post-treatment PSA doubling time less than 3 months followingeither surgery or radiation for localized or locally advanced prostate cancercan be a surrogate marker for eventual-perhaps inevitable-death from thedisease, according to data from a multicenter study of nearly 9,000 cancerpatients.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
5






